Webcast Alert: Aastrom Announces Conference Call to Discuss the Results from the U.S. Phase I/II Severe Fracture Trial.ANN ARBOR, Mich. -- Aastrom Biosciences, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ASTM ASTM abbr. American Society for Testing and Materials ) announces the following Webcast: What: Aastrom Biosciences, Inc. Conference Call to Discuss the Results from the U.S. Phase I/II Severe Fracture Trial When: Monday, October 22, 2007 at 9:00 am (EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT ) Where: http://www.vcall.com/IC/CEPage.asp?ID=122247 How: * For live Internet access, simply log on to the web at the address above. * For phone access, interested parties should call toll-free (877) 407-9205 15 minutes before the start of the call to register and identify themselves as registrants of the "Aastrom Conference Call". Any registered caller on the toll-free line may ask for call operator for directions to be placed in the queue for the Question & Answer session. If calling from outside the U.S., please use the international phone number (201) 689-8054. * To download the podcast, simply log on to the web at the address above. Contact: Investor Relations Department, (734) 930-5777 or mail@aastrom.com If you are unable to participate during the live call, the webcast will be available for replay at http://www.investorcalendar.com/ until January 22, 2008. Through November 1, 2007, the audio replay of the call will be available by dialing toll-free (877) 660-6853, or from outside the U.S. (201) 612-7415. When prompted on the phone, the account # is: 286, and the conference ID# is: 259045. Aastrom is a leader in the development of autologous autologous /au·tol·o·gous/ (aw-tol´ah-gus) related to self; belonging to the same organism. au·tol·o·gous adj. 1. cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC TRC Noun (in South Africa) Truth and Reconciliation Commission: a commission which encourages people who committed human rights abuses or acts of terror during the apartheid era to reveal the truth about their crimes in return for immunity from prosecution ) Technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries affecting bone, vascular, cardiac, and neural tissues. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC Technology platform has positioned Aastrom to advance multiple products into clinical development. Currently, the Company has a bone regeneration product in Phase III development for the treatment of osteonecrosis osteonecrosis /os·teo·ne·cro·sis/ (os?te-o-ne-kro´sis) necrosis of a bone. os·te·o·ne·cro·sis n. Necrosis of bone. of the femoral femoral /fem·o·ral/ (fem´or-al) pertaining to the femur or to the thigh. fem·o·ral adj. Of or relating to the femur or thigh. head (called the ON-CORE trial), a vascular regeneration product in Phase IIb development for the treatment of critical limb ischemia (called the RESTORE-CLI trial), and preclinical research programs targeting unmet needs in cardiac and neural health. Aastrom product candidates to treat osteonecrosis of the femoral head and dilated cardiomyopathy have been designated for orphan drug status by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. . For more information, visit Aastrom's website at www.aastrom.com. (astmc) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion